TACE DOWNSTAGING
TO TRANSPLANT ELIGIBILITY
For HCC patients who present beyond Milan criteria but within downstaging protocol boundaries, TACE offers a pathway to liver transplantation — the only potentially curative treatment for HCC in cirrhotic patients. Understanding who is eligible, what the process involves, and what outcomes to expect is critical for patients in this situation.
analyticsAt a Glance
- check_circle~70% of carefully selected patients achieve successful downstaging to within Milan criteria with TACE
- check_circleUNOS downstaging protocol: defined starting tumour burden limits; minimum 3-month observation after achieving Milan; relisting permitted
- check_circlePost-transplant 5-year survival in successful downstagees: 62–75% — comparable to patients listed within Milan
- check_circleAFP level and response pattern are the strongest predictors of downstaging durability and post-transplant outcome
What Is Downstaging and Why Does It Matter?
Milan criteria — single nodule ≤5 cm, or up to three nodules all ≤3 cm, no vascular invasion, no extrahepatic spread — were established by Mazzaferro in 1996 as the thresholds beyond which liver transplantation outcomes deteriorate significantly. However, a patient who presents with a 6 cm single HCC nodule is biologically very different from one with diffuse multifocal disease — and if TACE can shrink that 6 cm lesion to 4 cm with complete necrosis of the margins, the post-transplant prognosis may be indistinguishable from a patient who was always within Milan.
“Downstaging is not just a staging game — it is a biological test. Patients whose tumours respond well to locoregional therapy and remain controlled during observation demonstrate favourable tumour biology — the same patients who tend to do well after transplantation.”
Downstaging vs Bridging: A Critical Distinction
Bridging therapy maintains a patient who is already within Milan criteria during the transplant wait. Downstaging therapy attempts to reduce a patient who is beyond Milan into Milan criteria — a fundamentally different clinical goal. A patient undergoing downstaging is not yet on the transplant list; they must achieve and sustain a response before listing is considered. The observation period after achieving downstaging criteria serves as a biological selection test.
The Biological Selection Rationale
Requiring a minimum 3–6 month observation period after achieving Milan criteria is not administrative delay — it identifies tumours that are likely to remain controlled after transplantation versus those that will recur early despite surgical removal of the primary lesion. Tumours that progress again quickly after initial response have aggressive biology that will manifest post-transplant as recurrence. The observation period selects for biologically favourable disease.
Downstaging Protocols: UNOS, UCSF, and Major Programme Criteria
Several downstaging protocols have been developed and validated. The UNOS protocol is the most widely adopted in the United States; UCSF extended criteria and similar programmes exist globally.
| Protocol | Starting Tumour Burden Eligible | Required Response | Observation Period | Outcomes |
|---|---|---|---|---|
| UNOS Downstaging Protocol (US standard) | Single lesion >5 cm and ≤8 cm; OR 2–3 lesions with at least one >3 cm, total ≤8 cm; OR 4–5 lesions all ≤3 cm, total ≤8 cm; No macrovascular invasion; No extrahepatic spread | Reduction to within Milan criteria on imaging | Minimum 3 months from achieving Milan criteria before transplant listing; stable or improving response required at listing | 5-year post-transplant OS: 62–73% — comparable to within-Milan outcomes in most series |
| UCSF Extended Criteria (California) | Single lesion ≤6.5 cm; OR 2–3 lesions, largest ≤4.5 cm, total ≤8 cm — slightly more liberal than Milan, used in some centres for primary listing | Downstaging to within UCSF criteria or within Milan criteria | 3–6 months observation; AFP <500 ng/mL or declining at listing | 5-year OS 75% in successful downstagees within UCSF criteria |
| RETREAT Score (post-transplant recurrence predictor) | Not a downstaging protocol — a post-transplant risk score based on AFP slope, microvascular invasion, and explant tumour size | Used to risk-stratify downstaged patients for post-transplant recurrence surveillance intensity | N/A — applied at time of transplant | Higher RETREAT score predicts HCC recurrence post-transplant — guides surveillance protocol |
| Chinese Centre Protocols | Variable — most follow UNOS or Milan-equivalent criteria; some programmes use expanded criteria (Hangzhou, Fudan) based on pathological rather than imaging criteria | Imaging response to within-programme criteria + AFP response | 3–6 months observation; some programmes use 6 months | 5-year OS 60–75% for successful downstaging in published Chinese series |
Downstaging Outcomes: Success Rates and Post-Transplant Survival
Published series from major transplant programmes document the following outcomes for TACE downstaging across different starting tumour burden categories.
TACE Downstaging: Success Rate and Post-Transplant Survival
Pooled from Mehta et al. (UCSF), Yao et al. (UCSF), and UNOS registry analysis; approximate values across published series
- Successful downstaging rate (initial UNOS-eligible burden)~70%
- 5-year OS post-transplant: successful downstagees65–75%
- 5-year OS post-transplant: within-Milan primary listing70–75%
- Post-transplant HCC recurrence: successful downstagees15–20%
Predictors of Successful Downstaging and Favourable Post-Transplant Outcome
Several factors predict which patients will achieve durable downstaging and excellent post-transplant outcomes — informing case-by-case decision-making at the transplant MDT.
| Factor | Favourable | Unfavourable / Higher Risk |
|---|---|---|
| AFP level at baseline | AFP <200 ng/mL — excellent prognosis; AFP 200–1000 ng/mL — acceptable | AFP >1,000 ng/mL — poor downstaging response rate and post-transplant recurrence predictor; some programmes exclude >1,000 |
| AFP trajectory during TACE | AFP declining ≥50% from baseline during TACE — strong favourable signal | AFP rising or plateau despite radiological response — discordant biology; poor post-transplant prognosis |
| Tumour response pattern | Complete necrosis of all target lesions on MRI (mRECIST CR or PR with NPV >80%) | Incomplete response; viable tumour at edges despite central necrosis; new intrahepatic lesions during treatment |
| Number of lesions | Solitary lesion beyond Milan — best prognosis after downstaging | ≥4 lesions at presentation — lower response rate and higher recurrence post-transplant |
| Vascular invasion | Absent | Any portal vein or hepatic vein tumour thrombus — absolute contraindication to downstaging pathway |
| Stability during observation | Stable or continued response for ≥3 months after achieving Milan | Any progression beyond Milan during observation period — indicates aggressive biology; remove from downstaging pathway |
| Prior TACE response history | Complete response at prior TACE sessions — predicts durable future control | Multiple sessions with only partial responses — may indicate aggressive or refractory disease biology |
Downstaging vs Alternative Management for Beyond-Milan HCC
For patients beyond Milan criteria, downstaging to transplant is not the only option — it must be compared to other management strategies for shared decision-making.
Downstaging Pathway (Eligible Patients)
- Only curative option for cirrhotic patientsTransplantation removes both the tumour and the cirrhotic risk field — the only treatment that addresses both simultaneously. No other modality achieves this for patients with underlying cirrhosis.
- 5-year OS 65–75% for successful downstageesComparable to within-Milan transplant outcomes — patients who achieve durable downstaging have excellent long-term prognosis.
- Biological selection improves cohort qualityThe observation period and response requirement filter out patients with aggressive biology — those who successfully downstage and remain stable have demonstrated favourable tumour biology.
- TACE sessions are low-risk and repeatableThe downstaging pathway is achievable without major surgery in Child-Pugh A/B patients — TACE sessions are well-tolerated and allow reassessment at each step.
Alternative Management (Non-Downstaging Path)
- TACE + sorafenib/lenvatinib (systemic + locoregional)For patients too far beyond Milan or with rapidly progressive disease — TACE combined with systemic therapy (sorafenib, lenvatinib, atezolizumab + bevacizumab) can provide meaningful disease control and survival extension.
- Y-90 radioembolisation for large single lesionsY-90 achieves excellent control of large single HCC lesions (4–10 cm) and may achieve downstaging comparable to TACE — with better control at the ablation margin for large lesions near vessels.
- Surgical resection (non-cirrhotic or well-compensated)For patients with well-compensated (Child-Pugh A5/6) cirrhosis and a single large lesion beyond Milan — hepatic resection may achieve complete tumour removal without transplant if adequate functional liver remnant exists.
- Systemic therapy alone (advanced/metastatic)For patients whose disease extent (vascular invasion, extrahepatic spread) makes transplantation impossible regardless of locoregional response — systemic therapy is the appropriate strategy.
More from the TACE Resource Library
Continue exploring TACE — from bridging therapy and combination strategies to clinical evidence and access guides.
Frequently Asked Questions
Common questions from HCC patients exploring TACE downstaging as a pathway to transplant.
About TACE Downstaging
My AFP is 1,500 ng/mL — does this exclude me from downstaging?
A baseline AFP above 1,000 ng/mL is a recognised poor prognostic marker for downstaging success and post-transplant recurrence. Some transplant programmes use AFP >1,000 ng/mL as an exclusion criterion for the downstaging pathway because the high AFP reflects tumour biology (poorly differentiated, higher microvascular invasion rate) that predicts recurrence even after successful imaging downstaging. However, the trajectory of AFP during TACE treatment may be as important as the absolute value — if AFP falls by ≥50% within the first 1–2 TACE sessions to below 500 ng/mL, this biological response may be sufficient for continued consideration at specialist programmes. This assessment requires individualised review at a transplant MDT, not a binary rule. CancerFax can arrange a specialist consultation to assess your specific AFP trend and downstaging candidacy.
How long is the observation period before I can be listed for transplant after downstaging?
The UNOS downstaging protocol requires a minimum 3-month observation period after achieving within-Milan criteria on imaging — during which the patient must demonstrate stable or improving disease without progression beyond Milan. Most programmes extend this to 6 months in practice, particularly for patients who started with high AFP or large tumour burden. At the end of the observation period, a fresh cross-sectional MRI confirms sustained Milan criteria compliance. If confirmed, the patient is listed with MELD exception points equivalent to a within-Milan patient. If any progression beyond Milan occurs during observation, the patient is removed from the downstaging pathway and alternative management is required.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could TACE Downstaging Make You Transplant Eligible?
CancerFax reviews your imaging, AFP, Child-Pugh score, and tumour burden to assess whether you meet downstaging protocol eligibility — and connects you with transplant hepatologists and interventional radiologists in China and India who manage the complete downstaging-to-transplant pathway.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.